Core Insights - Zai Lab (ZLAB.US) shares rose over 5%, reaching $19.72, following the announcement of its strategic focus and clinical development progress at the 44th J.P. Morgan Healthcare Conference [1] Group 1: Company Developments - Zai Lab introduced its strategic priorities for 2026, highlighting the potential of Zocilurtatug pelitecan (Zoci) to become its first globally marketed product in the oncology field [1] - The company plans to initiate three pivotal registration studies by the end of 2026, targeting second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer [1]

Core Insights - Zai Ding Pharmaceutical (ZLAB.US) saw a stock increase of over 5%, reaching $19.72 on Wednesday [1] - The company presented its strategic focus and clinical development progress for 2026 at the 44th J.P. Morgan Healthcare Conference [1] - Zocilurtatug pelitecan (Zoci) is expected to be the company's first globally marketed product in the oncology field, with plans to initiate three pivotal registration studies by the end of 2026 [1] Company Developments - The three pivotal studies will target second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer [1]

Core Viewpoint - Zocilurtatugpelitecan (Zoci) is expected to become the first globally marketed product in the oncology field for the company, with plans to initiate three pivotal registration studies by the end of 2026 [1] Group 1: Company Developments - The company's stock price increased by over 7%, reaching 15.7 HKD with a trading volume of 185 million HKD [1] - The company currently has eight commercialized products in China, indicating a diversified and sustainable commercialization pipeline [1] - The product Nanfangmeilin Qusi Luan Capsule is expected to be launched in the first half of 2026, focusing on physician education and real-world evidence generation [1] Group 2: Strategic Plans - The company presented its 2026 strategic priorities and clinical development progress at the 44th JPMorgan Healthcare Conference [1] - The upcoming pivotal studies for Zoci will target second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer [1] - Other products expected to launch soon, such as povetacicept and elegrobart (VRDN-003), will further drive regional business growth [1]